Journal: medRxiv

Article Title: Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

doi: 10.1101/2021.08.26.21262468

Figure Lengend Snippet: (A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) SARS-CoV-2 S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.

Article Snippet: Functional neutralization capacity was investigated using a commercially available ELISA-based SARS-CoV-2 RBD-ACE2 binding inhibition assay (surrogate SARS-CoV-2 neutralization test (sVNT) cPass (medac GmbH, https://international.medac.de ).

Techniques: Microarray, Neutralization, MANN-WHITNEY, Inhibition, Release Assay

Journal: medRxiv

Article Title: Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

doi: 10.1101/2021.08.26.21262468

Figure Lengend Snippet: ( A ) Anti-SARS-CoV-2 N, ( B ) RBD- ( C ) and full-spike IgG measured in the serum of BNT162b2 vaccinated HCW and elderly persons six months after the first vaccination. ( D ) Neutralizing capacity was measured by sVNT and ( E ) serum neutralization against Alpha (B.1.1.7) VOC detected by pNT in vaccinated HCW and elderly persons six months after the first vaccination. ( F ) Binding capacity of serum IgG against six different RBDs of SARS-CoV-2 variants carrying the indicated mutations in HCW and elderly, measured by ELISA. Dotted lines indicate the manufacturer’s threshold values: for anti-N, anti-RBD, and anti-full spike IgG ≥1 S/Co, for sVNT >30%, and the lower limit of detection (1:10 dilution) for pNT. Lines indicate the median and interquartile range except for pNT, where the geometric mean and 95% confidence interval are shown. P values were calculated by the non-parametric Mann Whitney U test or Kruskal-Wallis test with Dunn’s multiple comparisons test. S/Co: signal-to-cutoff, N: nucleocapsid protein, RBD: receptor-binding domain, sVNT: surrogate virus neutralization test, ACE2: angiotensin-converting enzyme 2, ID50: 50% inhibition dilution.

Article Snippet: Functional neutralization capacity was investigated using a commercially available ELISA-based SARS-CoV-2 RBD-ACE2 binding inhibition assay (surrogate SARS-CoV-2 neutralization test (sVNT) cPass (medac GmbH, https://international.medac.de ).

Techniques: Neutralization, Binding Assay, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY, Inhibition

Journal: Viruses

Article Title: Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants

doi: 10.3390/v14020230

Figure Lengend Snippet: Analysis of mAb 9G8 blocking the SARS-CoV-2 spike RBD variant from binding to the human ACE2 receptor by surrogate virus neutralization test (sVNT). The percent inhibition of mAb 9G8 was measured against RBD of SARS-CoV-2 WT or SARS-CoV-2 variants such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Delta Plus/AY.1 (B.1.617.2.1), and Epsilon (B.1.429/7). The mAb 6C8 specific for nucleocapsid protein was used as a negative control. The results were expressed as the arithmetic mean of percent-blocking values of triplicates and ±SD of the mean.

Article Snippet: To determine the neutralizing activity of mAbs against SARS-CoV-2 variants, a GenScript cPASS surrogate virus neutralization test (sVNT) was performed according to manufacturer’s instructions (GenScript, Piscataway, NJ, USA).

Techniques: Blocking Assay, Variant Assay, Binding Assay, Virus, Neutralization, Inhibition, Negative Control

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance of each kit in discriminating SARS-CoV-2 infection.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques: Infection

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance for representativeness of neutralizing activity using the pre-defined cut-off values of each immunoassay kit.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Titer correlation of the analytical performance of the prediction of neutralizing activity using newly calculated cut-off values determined using Youden’s index.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Serial kinetics of antibody titers measured with each method: (A) PRNT ND50, (B.) GenScript cPass sVNT, (C) Roche Elecsys Anti-SARS-CoV-2, (D) Roche Elecsys Anti-SARS-CoV2 S, and (E) Abbott AdviseDx SARS-CoV2 IgG II.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Antibody titers by timeline.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Scatter plot and Pearson’s correlation for each method grouped with acute/convalescent phase. (A) GenScript cPass sVNT, (B) Roche Elecsys Anti-SARS-CoV-2, (C) Roche Elecsys Anti-SARS-CoV2 S, and (D) Abbott AdviseDx SARS-CoV2 IgG II were compared with PRNT, respectively. Each colored line depicts the linear regression model and the surrounding grey-colored area represents the 95% confidence interval.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance of each kit in discriminating SARS-CoV-2 infection.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques: Infection

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance for representativeness of neutralizing activity using the pre-defined cut-off values of each immunoassay kit.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Titer correlation of the analytical performance of the prediction of neutralizing activity using newly calculated cut-off values determined using Youden’s index.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Serial kinetics of antibody titers measured with each method: (A) PRNT ND50, (B.) GenScript cPass sVNT, (C) Roche Elecsys Anti-SARS-CoV-2, (D) Roche Elecsys Anti-SARS-CoV2 S, and (E) Abbott AdviseDx SARS-CoV2 IgG II.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Antibody titers by timeline.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Scatter plot and Pearson’s correlation for each method grouped with acute/convalescent phase. (A) GenScript cPass sVNT, (B) Roche Elecsys Anti-SARS-CoV-2, (C) Roche Elecsys Anti-SARS-CoV2 S, and (D) Abbott AdviseDx SARS-CoV2 IgG II were compared with PRNT, respectively. Each colored line depicts the linear regression model and the surrounding grey-colored area represents the 95% confidence interval.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques:

Journal: Biochemical and Biophysical Research Communications

Article Title: Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera

doi: 10.1016/j.bbrc.2023.01.052

Figure Lengend Snippet: Graphical illustration of the principle of a surrogate SARS-CoV-2 virus neutralization test. (A) cPass sVNT kit (Genscript Biotech) and (B) a biotin-based sVNT (in this study). Biotin-based sVNTs use biotinylated RBD for the detection of h ACE2 that has not been inhibited by neutralization antibodies via HRP-conjugated streptavidin.

Article Snippet: Graphical illustration of the principle of a surrogate SARS-CoV-2 virus neutralization test. (A) cPass sVNT kit (Genscript Biotech) and (B) a biotin-based sVNT (in this study).

Techniques: Virus, Neutralization

Journal: Biochemical and Biophysical Research Communications

Article Title: Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera

doi: 10.1016/j.bbrc.2023.01.052

Figure Lengend Snippet: Correlation among cPass sVNTs, biotin-based sVNTs, and pVNTs and negative cut-off determination (A). Biotin-based sVNT and cPass sVNT (B), Biotin-based sVNT and pVNT (C), and cPass sVNT and pVNT. (D) Negative cut-off determination. Correlation analyses of the biotin-based sVNTs, cPass sVNTs, and pVNTs using the sera of 100 selected participants with different SARS-CoV-2 neutralizing antibody levels and a negative cut-off test performed using a biotin-based sVNT kit. Correlation and linear regression analyses were performed using Pearson's correlation coefficient. Statistical significance was calculated using a two-tailed t -test. The data presented are the inhibition of h ACE2 and RBD binding to modified sVNT, cPass, or pVNT and are averages of three independent experiments. The dotted line represents the standard deviation of the linear regression plot.

Article Snippet: Graphical illustration of the principle of a surrogate SARS-CoV-2 virus neutralization test. (A) cPass sVNT kit (Genscript Biotech) and (B) a biotin-based sVNT (in this study).

Techniques: Two Tailed Test, Inhibition, Binding Assay, Modification, Standard Deviation

Journal: Analytical and Bioanalytical Chemistry

Article Title: Liposome-based high-throughput and point-of-care assays toward the quick, simple, and sensitive detection of neutralizing antibodies against SARS-CoV-2 in patient sera

doi: 10.1007/s00216-023-04548-3

Figure Lengend Snippet: Schematic of the developed high-throughput (i) and point-of care (ii) formats for the detection of neutralizing antibodies directed against the receptor binding domain of SARS-CoV-2. RBD-conjugated liposomes are incubated with patient serum and subsequently (i) immobilized in an ACE2-coated microplate or (ii) mixed with ACE2-biotin and added to a nitrocellulose membrane with streptavidin test line. In presence of neutralizing antibodies, no liposome-binding takes place, and no signals are observed in either format. In the absence of neutralizing antibodies liposomes are (i) bound in the microplate, enabling detection of the released sulforhodamine B via fluorescence after washing and lysis or (ii) bound by the test line, enabling a colorimetric detection via camera or naked eye

Article Snippet: Different competitive ELISAs relying on horseradish peroxidase (HRP)-conjugated RBD or ACE2 for detection are commercially available, such as the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit from GenScript®, the SARS-CoV-2 sVNT Kit from ProteoGenix, and the iFlash-2019-nCoV Neutralization Antibody Test from YHLO.

Techniques: High Throughput Screening Assay, Binding Assay, Incubation, Fluorescence, Lysis